Deep vein thrombosis

This is a good article. Click here for more information.
Source: Wikipedia, the free encyclopedia.
"DVT" redirects here. For other uses, see DVT (disambiguation).

Deep vein thrombosis
Other namesDeep venous thrombosis
unfractionated heparin, warfarin
FrequencyFrom 0.8–2.7 per 1000 people per year, but populations in China and Korea are below this range[8]

Deep vein thrombosis (DVT) is a type of

blood clot in a deep vein, most commonly in the legs or pelvis.[9][a] A minority of DVTs occur in the arms.[11] Symptoms can include pain, swelling, redness, and enlarged veins in the affected area, but some DVTs have no symptoms.[1]

The most common life-threatening concern with DVT is the potential for a clot to

ulcers.[5] Recurrent VTE occurs in about 30% of those in the ten years following an initial VTE.[3]

The mechanism behind DVT formation typically involves some combination of

antithrombin, protein C, and protein S and the mutations of factor V Leiden and prothrombin G20210A. In total, dozens of genetic risk factors have been identified.[4][14]

People suspected of having DVT can be assessed using a

ultrasound of the suspected veins.[5] VTE becomes much more common with age. The condition is rare in children, but occurs in almost 1% of those ≥ age 85 annually.[3] Asian, Asian-American, Native American, and Hispanic individuals have a lower VTE risk than Whites or Blacks.[4][15] Populations in Asia have VTE rates at 15 to 20% of what is seen in Western countries.[16]

Using

blood thinners is the standard treatment. Typical medications include rivaroxaban, apixaban, and warfarin. Beginning warfarin treatment requires an additional non-oral anticoagulant, often injections of heparin.[17][18][19] Prevention of VTE for the general population includes avoiding obesity and maintaining an active lifestyle. Preventive efforts following low-risk surgery include early and frequent walking. Riskier surgeries generally prevent VTE with a blood thinner or aspirin combined with intermittent pneumatic compression.[7]

Signs and symptoms

Image of a leg with "pitting" edema, a transient depression of the skin after pressure is applied. When this happens on one side, it increases the likelihood of DVT.
Swelling from fluid (edema) can result in "pitting" after pressure is applied. If this occurs only on one side, it raises the likelihood of DVT.

Symptoms classically affect a leg and typically develop over hours or days,[20] though they can develop suddenly or over a matter of weeks.[21] The legs are primarily affected, with 4–10% of DVT occurring in the arms.[11] Despite the signs and symptoms being highly variable,[5] the typical symptoms are pain, swelling, and redness. However, these symptoms might not manifest in the lower limbs of those unable to walk.[22] In those who are able to walk, DVT can reduce one's ability to do so.[23] The pain can be described as throbbing and can worsen with weight-bearing, prompting one to bear more weight with the unaffected leg.[21][24] Additional signs and symptoms include tenderness, pitting edema (see image), dilation of surface veins, warmth, discoloration, a "pulling sensation", and even cyanosis (a blue or purplish discoloration) with fever.[5][20][21] DVT can also exist without causing any symptoms.[22] Signs and symptoms help in determining the likelihood of DVT, but they are not used alone for diagnosis.[19]

At times, DVT can cause symptoms in both arms or both legs, as with bilateral DVT.

Migratory thrombophlebitis (Trousseau's syndrome) is a noted finding in those with pancreatic cancer and is associated with DVT.[27]

Potential complications

A

compression ultrasound.[30]

A rare and massive DVT that causes significant obstruction and discoloration (including cyanosis) is phlegmasia cerulea dolens.[31][32] It is life-threatening, limb-threatening, and carries a risk of venous gangrene.[33] Phlegmasia cerulea dolens can occur in the arm but more commonly affects the leg.[34][35] If found in the setting of acute compartment syndrome, an urgent fasciotomy is warranted to protect the limb.[36] Superior vena cava syndrome is a rare complication of arm DVT.[11]

DVT is thought to be able to cause a

patent foramen ovale is thought to allow clots to travel through the interatrial septum from the right atrium into the left atrium.[37][38]

  • A computed tomography image depicting PE in the pulmonary arteries
    A CT image with red arrows indicating PE (grey) in the
    pulmonary arteries
    (white)
  • Image showing marked discoloration of a leg with phlegmasia cerulea dolens
    A case of phlegmasia cerulea dolens in the left leg
  • A drawing depicting a patent foramen ovale
    A depiction of a patent foramen ovale

Differential diagnosis

In most suspected cases, DVT is ruled out after evaluation.

connective tissue disorders,[40] superficial vein thrombosis, muscle vein thrombosis, and varicose veins.[41]

Classification

Drawing showing that moving down the body, the inferior vena cava branches into 2 common iliac veins. The common iliac veins split into the internal iliac and external iliac veins. The external iliac veins give rise to the common femoral veins.
The iliac veins (in the pelvis) include the external iliac vein, the internal iliac vein, and the common iliac vein. The common femoral vein is below the external iliac vein. (It is labeled simply "femoral" here.)

DVT and PE are the two manifestations of the

venous thromboembolism (VTE).[2] VTE can occur as DVT only, DVT with PE, or PE only.[3] About two-thirds of VTE manifests as DVT only, with one-third manifesting as PE with or without DVT.[12] VTE, along with superficial vein thrombosis, are common types of venous thrombosis.[10]

DVT is classified as

chronic DVT persists more than 28 days.[42] Differences between these two types of DVT can be seen with ultrasound.[43] An episode of VTE after an initial one is classified as recurrent.[44][45] Bilateral DVT refers to clots in both limbs while unilateral means only a single limb is affected.[46]

DVT in a leg above the knee is termed proximal DVT (

common femoral vein;[51] elsewhere, it has been defined as involving at a minimum the common iliac vein, which is near the top of the pelvis.[19]

DVT can be classified into provoked and unprovoked categories.[52] For example, DVT that occurs in association with cancer or surgery can be classified as provoked.[52] However, the European Society of Cardiology in 2019 urged for this dichotomy to be abandoned to encourage more personalized risk assessments for recurrent VTE.[53] The distinction between these categories is not always clear.[54]

Causes

Artistic rendering of DVT
Depiction of DVT

Traditionally, the three factors of

endothelial blood vessel lining—contribute to VTE and were used to explain its formation.[55] More recently, inflammation has been identified as playing a clear causal role.[13] Other related causes include activation of immune system components, the state of microparticles in the blood, the concentration of oxygen, and possible platelet activation.[56] Various risk factors contribute to VTE, including genetic and environmental factors, though many with multiple risk factors never develop it.[57][58]

Acquired risk factors include the strong risk factor of older age,

Paget–Schroetter syndrome, where compression occurs near the base of the neck.[68][69][70]

Infections, including

systemic lupus erythematosus (SLE)[81] increase risk. SLE itself is frequently associated with secondary antiphospholipid syndrome.[82]

Cancer can grow in and around veins, causing venous stasis, and can also stimulate increased levels of tissue factor.

hormonal replacement therapy increase the risk through a variety of mechanisms, including altered blood coagulation protein levels and reduced fibrinolysis.[56]

Imagine showing the coagulation, which includes a group of proteins that regulate clots. DVT risk can be altered by abnormalities in the cascade.
The coagulation system, often described as a "cascade", includes a group of proteins that regulate clotting. DVT risk can be altered by abnormalities in the cascade. The regulators, antithrombin (ᾳTHR) and activated protein C (APC), are shown in green above the clotting factors they affect.

Dozens of genetic risk factors have been identified,

fibrinogen gamma gene variant rs2066865 have about a 1.6 times higher risk of VTE.[91] The genetic variant prothrombin G20210A, which increases prothrombin levels,[62] increases risk by about 2.5 times.[14] Additionally, approximately 5% of people have been identified with a background genetic risk comparable to the factor V Leiden and prothrombin G20210A mutations.[14]

Blood alterations including dysfibrinogenemia,[65] low free protein S,[58] activated protein C resistance,[58] homocystinuria,[92] hyperhomocysteinemia,[62] high fibrinogen levels,[62] high factor IX levels,[62] and high factor XI levels[62] are associated with increased risk. Other associated conditions include heparin-induced thrombocytopenia, catastrophic antiphospholipid syndrome,[93] paroxysmal nocturnal hemoglobinuria,[94] nephrotic syndrome,[58] chronic kidney disease,[95] polycythemia vera, essential thrombocythemia,[96] intravenous drug use,[97] and smoking.[d]

Some risk factors influence the location of DVT within the body. In isolated distal DVT, the profile of risk factors appears distinct from proximal DVT. Transient factors, such as surgery and immobilization, appear to dominate, whereas thrombophilias[e] and age do not seem to increase risk.[101] Common risk factors for having an upper extremity DVT include having an existing foreign body (such as a central venous catheter, a pacemaker, or a triple-lumen PICC line), cancer, and recent surgery.[11]

Pathophysiology

Blood has a natural tendency to clot when blood vessels are damaged (

coagulation cascade and the clearing of clots that are no longer needed is accomplished by the process of fibrinolysis. Reductions in fibrinolysis or increases in coagulation can increase the risk of DVT.[102]

DVT often develops in the calf veins and "grows" in the direction of venous flow, towards the heart.[42][103] DVT most frequently affects veins in the leg or pelvis[9] including the popliteal vein (behind the knee), femoral vein (of the thigh), and iliac veins of the pelvis. Extensive lower-extremity DVT can even reach into the inferior vena cava (in the abdomen).[104] Upper extremity DVT most commonly affects the subclavian, axillary, and jugular veins.[11]

The process of fibrinolysis, where DVT clots can be dissolved back into the blood, acts to temper the process of thrombus growth.

pathological development, in which collagen becomes the characteristic component. The first pathological stage is marked by red blood cells, and the second is characterized by medium-textured fibrin.[107]

An image showing major arm veins
Upper extremity DVTs can occur in the subclavian, axillary, brachial, ulnar, and radial veins (pictured) and the jugular and brachiocephalic veins (not pictured). The cephalic and basilic veins, however, are superficial veins.[11]

In arterial thrombosis, blood vessel wall damage is required, as it initiates

monocytes to release tissue factor.[109] Monocytes are also recruited early in the process.[55]

Tissue factor, via the tissue factor–

factor Xa, cytokines that promote endothelial dysfunction, and plasminogen activator inhibitor-1, which inhibits the breakdown of clots (fibrinolysis).[84]

Image depicting D-dimer production
D-dimer production

Often, DVT begins in the valves of veins.

microvesicles, which presumably begin clotting after binding to the endothelial surface.[86]

Anticoagulation, the standard treatment for DVT, prevents further clot growth and PE, but does not act directly on existing clots.[114]

Diagnosis

A

clinical probability assessment using the Wells score (see column in the table below) to determine if a potential DVT is "likely" or "unlikely" is typically the first step of the diagnostic process. The score is used in suspected first lower extremity DVT (without any PE symptoms) in primary care and outpatient settings, including the emergency department.[1][5] The numerical result (possible score −2 to 9) is most commonly grouped into either "unlikely" or "likely" categories.[1][5] A Wells score of two or more means DVT is considered "likely" (about a 28% chance), while those with a lower score are considered "unlikely" to have DVT (about a 6% chance).[39] In those unlikely to have DVT, a diagnosis is excluded by a negative D-dimer blood test.[1] In people with likely DVT, ultrasound is the standard imaging used to confirm or exclude a diagnosis.[5] Imaging is also needed for hospital inpatients with suspected DVT and those initially categorized as unlikely to have DVT but who have a positive D-dimer test.[1]

While the Wells score is the predominant and most studied clinical prediction rule for DVT,

pre-test probability assessment using clinical assessment and gestalt, but prediction rules are more reliable.[1]

Criteria Wells score for DVT[g] Dutch Primary Care Rule
Active cancer (treatment within last 6 months or palliative) +1 point +1 point
Calf swelling ≥ 3 cm compared to asymptomatic calf (measured 10 cm below
tibial tuberosity
) 		+1 point +2 points
Swollen unilateral superficial veins (non-varicose, in symptomatic leg) +1 point +1 point
Unilateral pitting edema (in symptomatic leg) +1 point —
Previous documented DVT +1 point —
Swelling of entire leg +1 point —
Localized tenderness along the deep venous system +1 point —
Paralysis, paresis, or recent cast immobilization of lower extremities +1 point —
Recently bedridden ≥ 3 days, or major surgery requiring regional or general anesthetic in the past 12 weeks +1 point +1 point
Alternative diagnosis at least as likely −2 points —
Positive D-dimer (≥ 0.5 mcg/mL or 1.7 nmol/L) — +6 points
Absence of leg trauma — +1 point
Male sex — +1 point
Use of oral contraceptives — +1 point[5][116]

Compression

color flow Doppler can be used to further characterize the clot[117] and Doppler ultrasound is especially helpful in the non-compressible iliac veins.[119]

CT scan venography, MRI venography, or a non-contrast MRI are also diagnostic possibilities.[120] The gold standard for judging imaging methods is contrast venography, which involves injecting a peripheral vein of the affected limb with a contrast agent and taking X-rays, to reveal whether the venous supply has been obstructed. Because of its cost, invasiveness, availability, and other limitations, this test is rarely performed.[39]

  • An ultrasound with a blood clot visible in the left common femoral vein. (The common femoral vein is distal to the external iliac vein.)
    An ultrasound with a blood clot visible in the left common femoral vein. (The common femoral vein is distal to the external iliac vein.)
  • Doppler ultrasonography showing absence of flow and hyperechogenic content in a clotted femoral vein (labeled subsartorial[h]) distal to the branching point of the deep femoral vein. When compared to this clot, clots that instead obstruct the common femoral vein (proximal to this branching point) cause more severe effects due to impacting a significantly larger portion of the leg.[122]
    Doppler ultrasonography showing absence of flow and hyperechogenic content in a clotted femoral vein (labeled subsartorial[h]) distal to the branching point of the deep femoral vein. When compared to this clot, clots that instead obstruct the common femoral vein (proximal to this branching point) cause more severe effects due to impacting a significantly larger portion of the leg.[122]
  • An abdominal CT scan demonstrating an iliofemoral DVT, with the clot in the right common iliac vein of the pelvis
    An abdominal CT scan demonstrating an iliofemoral DVT, with the clot in the right common iliac vein of the pelvis

Management

Treatment for DVT is warranted when the clots are either proximal, distal and symptomatic, or upper extremity and symptomatic.[2] Providing anticoagulation, or blood-thinning medicine, is the typical treatment after patients are checked to make sure they are not subject to bleeding.[2][i] However, treatment varies depending upon the location of DVT. For example, in cases of isolated distal DVT, ultrasound surveillance (a second ultrasound after 2 weeks to check for proximal clots), might be used instead of anticoagulation.[5][124] Although, those with isolated distal DVT at a high-risk of VTE recurrence are typically anticoagulated as if they had proximal DVT. Those at a low-risk for recurrence might receive a four to six week course of anticoagulation, lower doses, or no anticoagulation at all.[5] In contrast, those with proximal DVT should receive at least 3 months of anticoagulation.[5]

Some anticoagulants can be taken by mouth, and these oral medicines include

international normalized ratio (INR)[k] of 2.0–3.0, with 2.5 as the target.[128] The benefit of taking warfarin declines as the duration of treatment extends,[129] and the risk of bleeding increases with age.[130] Periodic INR monitoring is not necessary when first-line direct oral anticoagulants are used. Overall, anticoagulation therapy is complex and many circumstances can affect how these therapies are managed.[131]

Heparin
Fondaparinux
Structural representations of the backbone of heparins (left), which vary in the size of their chain, and the synthetic pentasaccaride (five-sugar) fondaparinux (right)

The duration of anticoagulation therapy (whether it will last 4 to 6 weeks,

decision making.[52] When proximal DVT is provoked by surgery or trauma a 3-month course of anticoagulation is standard.[19] When a first VTE is proximal DVT that is either unprovoked or associated with transient non-surgical risk factor, low-dose anticoagulation beyond 3 to 6 months might be used.[19] In those with an annual risk of VTE in excess of 9%, as after an unprovoked episode, extended anticoagulation is a possibility.[132] Those who finish warfarin treatment after idiopathic VTE with an elevated D-dimer level show an increased risk of recurrent VTE (about 9% vs about 4% for normal results), and this result might be used in clinical decision making.[133] Thrombophilia test results rarely play a role in the length of treatment.[80]

Treatment for acute leg DVT is suggested to continue at home for uncomplicated DVT instead of hospitalization. Factors that favor hospitalization include severe symptoms or additional medical issues.[12] Early walking is suggested over bedrest.[134] Graduated compression stockings—which apply higher pressure at the ankles and a lower pressure around the knees[126] can be trialed for symptomatic management of acute DVT symptoms, but they are not recommended for reducing the risk of post-thrombotic syndrome,[125] as the potential benefit of using them for this goal "may be uncertain".[5] Nor are compression stockings likely to reduce VTE recurrence.[135] They are, however, recommended in those with isolated distal DVT.[5]

If someone decides to stop anticoagulation after an unprovoked VTE instead of being on lifelong anticoagulation, aspirin can be used to reduce the risk of recurrence,[136] but it is only about 33% as effective as anticoagulation in preventing recurrent VTE.[52] Statins have also been investigated for their potential to reduce recurrent VTE rates, with some studies suggesting effectiveness.[137]

Investigations for cancer

An unprovoked VTE might signal the presence of an unknown cancer, as it is an underlying condition in up to 10% of unprovoked cases.

NICE recommends that further investigations are unwarranted in those without relevant signs or symptoms.[138]

Interventions

catheter-directed thrombolysis (the preferred method of administering the clot-busting enzyme[5]) include a risk of bleeding, complexity,[l] and the cost of the procedure.[125] Although, while anticoagulation is the preferred treatment for DVT,[125] thrombolysis is a treatment option for those with the severe DVT form of phlegmasia cerula dorens (bottom left image) and in some younger patients with DVT affecting the iliac and common femoral veins.[12] Of note, a variety of contraindications to thrombolysis exist.[125] In 2020, NICE kept their 2012 recommendations that catheter-directed thrombolysis should be considered in those with iliofemoral DVT who have "symptoms lasting less than 14 days, good functional status, a life expectancy of 1 year or more, and a low risk of bleeding."[138]

A mechanical thrombectomy device can remove DVT clots, particularly in acute iliofemoral DVT (DVT of the major veins in the pelvis), but there is limited data on its efficacy. It is usually combined with thrombolysis, and sometimes temporary IVC filters are placed to protect against PE during the procedure.

QALY.[144][145] Phlegmasia cerulea dolens might be treated with catheter-directed thrombolysis and/or thrombectomy.[19][143]

In DVT in the arm, the first (topmost) rib can be surgically removed as part of the typical treatment when the DVT is due to

Paget–Schroetter syndrome. This treatment involves initial anticoagulation followed by thrombolysis of the subclavian vein and staged first rib resection to relieve the thoracic outlet compression and prevent recurrent DVT.[146]

  • The first rib, which is removed in a first rib resection surgery, is labeled 1 in this image
    The first rib, which is removed in a first rib resection surgery, is labeled 1 in this image
  • A venogram before catheter-directed thrombolysis for Paget–Schroetter syndrome, a rare and severe arm DVT shown here in a judo practitioner, with highly restricted blood flow shown in the vein
    A venogram before catheter-directed thrombolysis for
    Paget–Schroetter syndrome
    , a rare and severe arm DVT shown here in a judo practitioner, with highly restricted blood flow shown in the vein
  • After treatment with catheter-directed thrombolysis, blood flow in the axillary and subclavian vein were significantly improved. Afterwards, a first rib resection allowed decompression. This reduces the risk of recurrent DVT and other sequelae from thoracic outlet compression.[147]
    After treatment with catheter-directed thrombolysis, blood flow in the
    sequelae from thoracic outlet compression.[147]
An IVC filter

The placement of an

absolutely contraindicated (not possible), or if someone develops a PE despite being anticoagulated.[138] However, a 2020 NICE review found "little good evidence" for their use.[138] A 2018 study associated IVC filter placement with a 50% reduction in PE, a 70% increase in DVT, and an 18% increase in 30 day mortality when compared to no IVC placement.[1][148] Other studies including a systematic review and meta-analysis did not find a difference in mortality with IVC placement.[30] If someone develops a PE despite being anticoagulated, care should be given to optimize anticoagulation treatment and address other related concerns before considering IVC filter placement.[138]

Field of medicine

Patients with a history of DVT might be managed by

vascular medicine.[149] Patients suspected of having an acute DVT are often referred to the emergency department for evaluation.[150] Interventional radiology is the specialty that typically places and retrieves IVC filters,[151] and vascular surgery might do catheter directed thrombosis for some severe DVTs.[147]

Prevention

For the

primary prevention (prevention of a first VTE), and the JUPITER trial, which used rosuvastatin, has provided some tentative evidence of effectiveness.[14][154] Of the statins, rosuvastatin appears to be the only one with the potential to reduce VTE risk.[155] If so, it appears to reduce risk by about 15%.[153] However, the number needed to treat to prevent one initial VTE is about 2000, limiting its applicability.[156]

Hospital (non-surgical) patients

Acutely ill hospitalized patients are suggested to receive a parenteral anticoagulant, although the potential net benefit is uncertain.[63] Critically ill hospitalized patients are recommended to either receive unfractionated heparin or low-molecular weight heparin instead of foregoing these medicines.[63]

After surgery

knee replacement surgery
, a procedure that can precipitate DVT formation

Major orthopedic surgery—

total knee replacement, or hip fracture surgery—has a high risk of causing VTE.[157] If prophylaxis is not used after these surgeries, symptomatic VTE has about a 4% chance of developing within 35 days.[158] Following major orthopedic surgery, a blood thinner or aspirin is typically paired with intermittent pneumatic compression, which is the preferred mechanical prophylaxis over graduated compression stockings.[7]

Options for VTE prevention in people following non-orthopedic surgery include early walking, mechanical prophylaxis, and blood thinners (low-molecular-weight heparin and low-dose-unfractionated heparin) depending upon the risk of VTE, risk of major bleeding, and person's preferences.[159] After low-risk surgeries, early and frequent walking is the best preventive measure.[7]

Pregnancy

The risk of VTE is increased in pregnancy by about four to five times because of a more hypercoagulable state that protects against fatal

postpartum hemorrhage.[28] Preventive measures for pregnancy-related VTE were suggested by the American Society of Hematology in 2018.[160] Warfarin, a common vitamin K antagonist, can cause birth defects and is not used for prevention during pregnancy.[161]

Travelers

An example of a compression stocking

Travelling "is an often cited yet relatively uncommon" cause of VTE.[28] Suggestions for at-risk[n] long-haul travelers include calf exercises, frequent walking, and aisle seating in airplanes to ease walking.[162][163] Graduated compression stockings have sharply reduced the levels of asymptomatic DVT in airline passengers, but the effect on symptomatic DVT, PE, or mortality is unknown, as none of the individuals studied developed these outcomes.[164] However, graduated compression stockings are not suggested for long-haul travelers (>4 hours) without risk factors for VTE. Likewise, neither aspirin nor anticoagulants are suggested in the general population undertaking long-haul travel.[63] Those with significant VTE risk factors[o] undertaking long-haul travel are suggested to use either graduated compression stockings or LMWH for VTE prevention. If neither of these two methods are feasible, then aspirin is suggested.[63]

Prognosis

DVT is most frequently a disease of older age that occurs in the context of nursing homes, hospitals, and active cancer.[3] It is associated with a 30-day mortality rate of about 6%, with PE being the cause of most of these deaths.[1] Proximal DVT is frequently associated with PE, unlike distal DVT, which is rarely if ever associated with PE.[39] Around 56% of those with proximal DVT also have PE, although a chest CT is not needed simply because of the presence of DVT.[1] If proximal DVT is left untreated, in the following 3 months approximately half of people will experience symptomatic PE.[9]

Another frequent complication of proximal DVT, and the most frequent chronic complication, is post-thrombotic syndrome, where individuals have chronic venous symptoms.

leg ulcers.[5] After proximal DVT, an estimated 20–50% of people develop the syndrome, with 5–10% experiencing severe symptoms.[165] Post-thrombotic syndrome can also be a complication of distal DVT, though to a lesser extent than with proximal DVT.[166]

In the 10 years following an initial VTE, about 30% of people will have a recurrence.[3] VTE recurrence in those with prior DVT is more likely to recur as DVT than PE.[167] Cancer[5] and unprovoked DVT are strong risk factors for recurrence.[60] After initial proximal unprovoked DVT with and without PE, 16–17% of people will have recurrent VTE in the 2 years after they complete their course of anticoagulants. VTE recurrence is less common in distal DVT than proximal DVT.[44][45] In upper extremity DVT, annual VTE recurrence is about 2–4%.[130] After surgery, a provoked proximal DVT or PE has an annual recurrence rate of only 0.7%.[60]

Epidemiology

About 1.5 out of 1000 adults a year have a first VTE in high-income countries.[168][169] The condition becomes much more common with age.[3] VTE rarely occurs in children, but when it does, it predominantly affects hospitalized children.[170] Children in North America and the Netherlands have VTE rates that range from 0.07 to 0.49 out of 10,000 children annually.[170] Meanwhile, almost 1% of those aged 85 and above experience VTE each year.[3] About 60% of all VTEs occur in those 70 years of age or older.[9] Incidence is about 18% higher in males than in females,[4] though there are ages when VTE is more prevalent in women.[15] VTE occurs in association with hospitalization or nursing home residence about 60% of the time, active cancer about 20% of the time, and a central venous catheter or transvenous pacemaker about 9% of the time.[3]

During pregnancy and after childbirth, acute VTE occurs in about 1.2 of 1000 deliveries. Despite it being relatively rare, it is a leading cause of maternal morbidity and

mortality.[160] After surgery with preventive treatment, VTE develops in about 10 of 1000 people after total or partial knee replacement, and in about 5 of 1000 after total or partial hip replacement.[171] About 400,000 Americans develop an initial VTE each year, with 100,000 deaths or more attributable to PE.[169] Asian, Asian-American, Native American, and Hispanic individuals have a lower VTE risk than Whites or Blacks.[4][15] Populations in Asia have VTE rates at 15 to 20% of what is seen in Western countries, with an increase in incidence seen over time.[16] In North American and European populations, around 4–8% of people have a thrombophilia,[89] most commonly factor V leiden and prothrombin G20210A. For populations in China, Japan, and Thailand, deficiences in protein S, protein C, and antithrombin predominate.[172] Non-O blood type is present in around 50% of the general population and varies with ethnicity, and it is present in about 70% of those with VTE.[90][173]

DVT occurs in the upper extremities in about 4–10% of cases,[11] with an incidence of 0.4–1.0 people out of 10,000 a year.[5] A minority of upper extremity DVTs are due to Paget–Schroetter syndrome, also called effort thrombosis, which occurs in 1–2 people out of 100,000 a year, usually in athletic males around 30 years of age or in those who do significant amounts of overhead manual labor.[69][147]

Social

Serena Williams has spoken at length about a frightening encounter she had with VTE while she was hospitalized in 2017.[174]

Being on blood thinners because of DVT can be life-changing because it can prevent lifestyle activities such as contact or winter sports to prevent bleeding after potential injuries.[175] Head injuries prompting brain bleeds are of particular concern. This has caused NASCAR driver Brian Vickers to forego participation in races. Professional basketball players including NBA players Chris Bosh and hall of famer Hakeem Olajuwon have dealt with recurrent blood clots,[176] and Bosh's career was significantly hampered by DVT and PE.[177]

Tennis star

C-section surgery and was off of blood thinners. After feeling the sudden onset of a PE symptom, shortness of breath, she told her nurse and requested a CT scan and an IV heparin drip, all while gasping for air. She started to receive an ultrasound to look for DVT in the legs, prompting her to express dissatisfaction to the medical staff that they were not looking for clots where she had symptoms (her lungs), and they were not yet treating her presumed PE. After being diagnosed with PE and not DVT, and after receiving heparin by IV, the coughing from the PE caused her C-section surgical site to open and the heparin contributed to bleeding at the site. Serena later received an IVC filter while in the hospital.[174][179]

Other notable people have been affected by DVT. Former United States (US) President

Jimmy Stewart had DVT that progressed to a PE when he was 89.[183][186]

History

Rudolf Virchow

The book

Ayurvedic text published around 600–900 BC, contains what has been cited as the first description of DVT.[187] In 1271, DVT symptoms in the leg of a 20-year-old male were described in a French manuscript, which has been cited as the first case or the first Western reference to DVT.[187][188]

In 1856, German physician and pathologist Rudolf Virchow published his analysis after the insertion of foreign bodies into the jugular veins of dogs, which migrated to the pulmonary arteries. These foreign bodies caused pulmonary emboli, and Virchow was focused on explaining their consequences.[189] He cited three factors, which are now understood as hypercoaguability, stasis, and endothelial injury.[190] It was not until 1950 that this framework was cited as Virchow's triad,[189] but the teaching of Virchow's triad has continued in light of its utility as a theoretical framework and as a recognition of the significant progress Virchow made in expanding the understanding of VTE.[189][190]

Methods to observe DVT by ultrasound were established in the 1960s.

impedance plethysmography in the 1970s and 1980s,[191] but ultrasound, particularly after utility of probe compression was demonstrated in 1986, became the preferred diagnostic method.[187] Yet, in the mid-1990s, contrast venography and impedance plethysmography were still described as common.[192]

Warfarin, a common vitamin K antagonist, was the mainstay of pharmacological treatment for about 50 years.

Multiple pharmacological therapies for DVT were introduced in the 20th century: oral anticoagulants in the 1940s,

direct oral anticoagulants (DOACs) were developed.[195] In the late 2000s to early 2010s, DOACs—including rivaroxaban (Xarelto), apixaban (Eliquis), and dabigatran (Pradaxa)—came to the market.[60] The New York Times described a "furious battle" among the three makers of these drugs "for the prescription pads of doctors".[194]

Economics

VTE costs the US healthcare system about $7 to 10 billion dollars annually.[169] Initial and average DVT costs for a hospitalized US patient is about $10,000 (2015 estimate).[196] In Europe, the costs for an initial VTE hospitalization are significantly less, costing about €2000 to 4000 (2011 estimate).[197] Post-thrombotic syndrome is a significant contributor to DVT follow-up costs.[198] Outpatient treatment significantly reduces costs, and treatment costs for PE exceed those of DVT.[199]

Research directions

A 2019 study published in Nature Genetics reported more than doubling the known genetic loci associated with VTE.[14] In their updated 2018 clinical practice guidelines, the American Society of Hematology identified 29 separate research priorities, most of which related to patients who are acutely or critically ill.[63] Inhibition of factor XI, P-selectin, E-selectin, and a reduction in formation of neutrophil extracellular traps are potential therapies that might treat VTE without increasing bleeding risk.[200]

Notes

  1. retinal vein thrombosis), spleen and intestines (splanchnic vein thrombosis), liver (Budd–Chiari syndrome), kidneys (renal vein thrombosis), and ovaries (ovarian vein thrombosis) are more unusual forms of venous thrombosis and they are considered as separate diseases.[10]
  2. combined oral contraceptives (COCs) have an approximate two to three times higher risk than second-generation COCs.[64] Progestogen-only pill use is not associated with increased VTE risk.[87]
  3. ^ Type I[58]
  4. ^ "It is important to note that smoking is not an independent risk factor, although it increases the risk for cancers and other comorbidities and works synergistically with other independent risk factors."[98]
  5. ^ The term 'thrombophilia' as used here applies to the five inherited abnormalities of antithrombin, protein C, protein S, factor V, and prothrombin, as is done elsewhere.[89][99] These 5 genetic factors have been referred to as the classical thrombophilias.[100]
  6. ^ An elevated level is greater than 250 ng/mL D-dimer units (DDU) or greater than 0.5 μg/mL fibrinogen equivalent units (FEU). A normal level is below these values.[113]
  7. ^ The Wells score as displayed here is the more recent modified score, which added a criterion for a previous documented DVT and increased the time range after surgery to 12 weeks from 4 weeks.[117]
  8. ^ Subsartorial is a proposed name for a section of the femoral vein.[121]
  9. NSAIDs.[123]
  10. ^ The international normalized ratio should be ≥ 2.0 for 24 hours minimum,[18] but if the ratio is > 3.0, then the parenteral anticoagulant is not needed for five days.[126]
  11. ^ An INR is determined from the ratio of a patient's prothrombin time (PT) to a standardized control PT. A normal INR for those not on anticoagulation is 1.0. A value of 5.0 or higher is considered a critical finding because of an increased risk of bleeding.[127]
  12. ^ "Up to 83% of patients treated by any catheter-based therapy, need adjunctive angioplasty, and stenting".[5]
  13. ^ Estimated in United States dollars, estimate published in 2019
  14. ^ Including those with "previous VTE, recent surgery or trauma, active malignancy, pregnancy, estrogen use, advanced age, limited mobility, severe obesity, or known thrombophilic disorder"[162]
  15. ^ For example "recent surgery, history of VTE, postpartum women, active malignancy, or ≥2 risk factors, including combinations of the above with hormone replacement therapy, obesity, or pregnancy"[63]

References

  1. ^
    S2CID 173995098
    .
  2. ^
    S2CID 3707226
    .
  3. ^
    PMID 26780736
    .
  4. ^
    PMID 27764878
    .
  5. ^
    PMID 28329262
    .
  6. ^ a b "What is Venous Thromboembolism?". Centers for Disease Control and Prevention. 14 March 2019. Retrieved 6 January 2020.
  7. ^
    PMID 31794602
    .
  8. PMID 25304324
    .
  9. ^
    PMID 29297660. Archived from the original
    on 30 January 2020. Retrieved 30 January 2020.
  10. ^
    PMID 31917405
    .
  11. ^
    PMID 28446351
    .
  12. ^
    PMID 33007077
    .
  13. ^
    PMID 31736432
    .
  14. ^
    PMID 31676865
    .
  15. ^
    PMID 27126645
    .
  16. ^
    PMID 29212112
    .
  17. ^
    PMID 23531017
    .
  18. ^ a b c Guyatt et al. 2012, p. 20S: 2.4.
  19. ^
    S2CID 73433650
    .
  20. ^
    S2CID 34922038
    .
  21. ^
    PMID 18296592
    .
  22. ^
    PMID 18031292
    .
  23. PMID 20066826. Archived
    (PDF) from the original on 6 February 2013.
  24. S2CID 3454404
    .
  25. S2CID 30043830
    .
  26. PMID 11762276
    .
  27. PMID 31327867
    .
  28. ^
    PMID 29872243
    .
  29. ^
    PMID 29101916
    .
  30. ^
    PMID 31504429
    .
  31. S2CID 64951
    .
  32. PMID 12997687
    .
  33. PMID 29422736
    .
  34. ^ Owings JT (2005). "Management of venous thromboembolism". ACS Surgery. American College of Surgeons. Archived from the original on 27 January 2012. Retrieved 16 January 2012.
  35. PMID 30443615
    .
  36. PMID 27113791
    .
  37. PMID 32431661
    .
  38. PMID 30141306
    .
  39. ^
    PMID 22315267
    .
  40. PMID 18205917
    .
  41. PMID 22959541
    .
  42. ^
    PMID 31258531
    .
  43. PMID 28123971
    .
  44. ^
    PMID 31340984
    .
  45. ^
    S2CID 242392407
    .
  46. S2CID 30043830
    .
  47. PMID 20124539
    .
  48. PMC 2072980
    .
  49. S2CID 33536953
    .
  50. PMID 27437827
    .
  51. PMID 30586751
    .
  52. ^
    PMID 31917402
    .
  53. PMID 33733032
    .
  54. ^ Piazza G (19 October 2019). "Clot Chronicles: unprovoked vs. provoked VTE". North American Thrombosis Forum. Archived from the original on 8 May 2021. Retrieved 8 May 2021.
  55. ^
    S2CID 211037046
    .
  56. ^
    PMID 22345594
    .
  57. PMID 21116184
    .
  58. ^
    PMID 20456358
    .
  59. S2CID 49313388
    .
  60. ^
    PMID 23531017
    .
  61. PMID 21084000
    .
  62. ^
    S2CID 34486553
    .
  63. ^
    PMID 30482763
    .
  64. ^
    S2CID 13564168
    .
  65. ^
    PMID 19630821
    .
  66. S2CID 207452463
    .
  67. PMID 27145936
    .
  68. PMID 29435334
    .
  69. ^
    PMID 29399532
    .
  70. PMID 25140182
    .
  71. PMID 31749809
    .
  72. PMID 26111103
    .
  73. PMID 33217420
    .
  74. PMID 32407386
    .
  75. S2CID 220337035
    .
  76. S2CID 49606106
    .
  77. ^
    PMID 29876337
    .
  78. PMID 32375490
    .
  79. PMID 30472725
    .
  80. ^
    S2CID 6925903
    .
  81. PMID 28331377
    .
  82. PMID 31957081
    .
  83. PMID 28917273
    .
  84. ^
    PMID 30918022
    .
  85. PMID 29255070
    .
  86. ^
    PMID 21034220
    .
  87. PMID 22872710
    .
  88. ^
    S2CID 23139811
    .
  89. ^
    S2CID 9305488
    .
  90. ^
    S2CID 5203474
    .
  91. PMID 31582554
    .
  92. PMID 26221164
    .
  93. PMID 26179082
    .
  94. PMID 25890452
    .
  95. PMID 30115029
    .
  96. PMID 22076463
    .
  97. S2CID 54379879
    .
  98. PMID 29262230
    .
  99. PMID 22160027
    .
  100. PMID 32731838
    .
  101. PMID 22082302
    .
  102. ^
    PMID 25294122
    .
  103. PMID 20351121
    .
  104. ^ Kim ES, Bartholomew JR. "Venous thromboembolism". Disease Management Project. Cleveland Clinic. Archived from the original on 23 February 2011. Retrieved 15 February 2011.
  105. ^
    PMID 21325673
    .
  106. PMID 29034034
    .
  107. ^
    PMID 32197363
    .
  108. PMID 19303501
    .
  109. ^
    PMID 27354721
    .
  110. ^
    PMID 31315434
    .
  111. S2CID 58594612
    .
  112. ^
    S2CID 22467822
    .
  113. ^ a b "DDI/9290 clinical: D-dimer, plasma". Mayo Medical Laboratories. Archived from the original on 8 October 2012. Retrieved 27 August 2012.
  114. PMID 23537968
    .
  115. PMID 24615063
    .
  116. ^
    PMID 31845779
    .
  117. ^
    PMID 29399531
    .
  118. ^
    S2CID 34220435
    .
  119. ^
    PMID 26149033
    .
  120. ^
    PMID 30122174
    .
  121. doi:10.7860/IJARS/2019/40329:2458
    .
  122. PMID 21422387
    .
  123. PMID 16437461
    .
  124. PMID 29399516
    .
  125. ^
    PMID 26867832
    .
  126. ^
    PMID 22315268
    .
  127. PMID 29939529
    .
  128. ^ Guyatt et al. 2012, p. 22S: 3.2.
  129. PMID 25092359
    .
  130. ^
    PMID 22734929
    .
  131. PMID 30482765
    .
  132. PMID 21671894
    .
  133. S2CID 10659607
    .
  134. PMID 30303669
    .
  135. PMID 26747198
    .
  136. PMID 31573167
    .
  137. PMID 29399524
    .
  138. ^ a b c d e f g National Institute for Health and Care Excellence. "NICE Guideline 158: Venous thromboembolic diseases: diagnosis, management and thrombophilia testing" London, 26 March 2020.
  139. S2CID 21801157
    .
  140. PMID 26853645
    .
  141. ^
    PMID 29211671
    .
  142. ^ Bhandari T (6 December 2017). "Clot-busting drugs not recommended for most patients with blood clots". Washington University School of Medicine. Retrieved 21 January 2020.
  143. ^ a b National Institute for Health and Care Excellence. "NICE Interventional procedures guidance 651: Percutaneous mechanical thrombectomy for acute deep vein thrombosis of the leg" London, 12 June 2019.
  144. PMID 30586751
    .
  145. PMID 31592728
    .
  146. PMID 31037504
    .
  147. ^
    PMID 26987584
    .
  148. PMID 30646021
    .
  149. ^ Moll S (9 May 2012). "What kind of doctor do I need?". Clot Connect. Archived from the original on 28 January 2020. Retrieved 28 January 2020.
  150. PMID 27429688
    .
  151. ^ "Inferior Vena Cava (IVC) Filter Placement". Johns Hopkins Medicine. 2020. Retrieved 28 January 2020.
  152. PMID 11054217
    .
  153. ^
    PMID 33191841
    .
  154. PMID 25518837
    .
  155. S2CID 24036108
    .
  156. PMID 23396492
    .
  157. S2CID 22797561
    .
  158. PMID 22315265
    .
  159. PMID 22315263
    .
  160. ^
    PMID 30482767
    .
  161. PMID 22315276
    .
  162. ^
    PMID 22315261
    . See section 6.0, Long-Distance Travel
  163. ^ "New DVT guidelines: No evidence to support "economy-class syndrome"". American College of Chest Physicians. 7 February 2012. Archived from the original on 3 June 2016. Retrieved 10 February 2012. oral contraceptives, sitting in a window seat, advanced age, and pregnancy increase DVT risk in long-distance travelers
  164. PMID 33878207
    .
  165. PMID 28844444
    .
  166. PMID 31899848
    .
  167. PMID 25173341
    .
  168. PMID 31385593
    .
  169. ^
    PMID 26654719
    .
  170. ^
    PMID 30482766
    .
  171. PMID 22253396
    .
  172. S2CID 17552169
    .
  173. ^ "Blood types". American Red Cross. Archived from the original on 14 August 2012. Retrieved 15 August 2012.
  174. ^ a b Haskell R (10 January 2018). "Serena Williams on motherhood, marriage, and making her comeback". Vogue. Retrieved 22 January 2020.
  175. S2CID 58564402
    .
  176. ^ Perez AJ (17 February 2016). "Expert: Chris Bosh, like many, at risk of blood clot recurrence". USA Today. Retrieved 22 January 2020.
  177. ^ Martin J (4 May 2016). "Chris Bosh officially out as Heat make playoff push". CNN. Retrieved 22 January 2020.
  178. ^ Moisse K (2 March 2011). "Serena Williams Hospitalized After Pulmonary Embolism". ABC News. Retrieved 22 January 2020.
  179. S2CID 231803661
    .
  180. PMID 23336651
    .
  181. ^ Frankel TC (11 September 2016). "Hillary Clinton has not been quick to share health information". The Washington Post. Retrieved 22 January 2020.
  182. ^ "Cheney diagnosed with deep-vein thrombosis". The Guardian. 6 March 2007. Retrieved 22 January 2020.
  183. ^ a b Rodriguez D (12 October 2018). "11 Celebrities Who Battled Deep Vein Thrombosis Risk". Everyday Health. Retrieved 22 January 2020.
  184. ^ "Coroner: Rapper Heavy D died of blood clot in lung". CNN. 27 December 2011. Retrieved 22 January 2020.
  185. ^ "My husband should be living today". TODAY. 3 March 2005. Retrieved 22 January 2020.
  186. ISBN 978-1400052226
    .
  187. ^
    PMID 24059395
    .
  188. PMID 23297815
    .
  189. ^
    PMID 20739582
    .
  190. ^
    PMID 18783400
    .
  191. ^ Dalen 2003, p. 3.
  192. PMID 8998158
    .
  193. ^ Dalen 2003, p. 2.
  194. ^ a b Ornstein C, Jones RG (7 January 2015). "The drugs that companies promote to doctors are rarely breakthroughs". The New York Times.
  195. ^
    PMID 27581829
    .
  196. PMID 25555319
    .
  197. PMID 21222564
    .
  198. S2CID 8966676
    .
  199. PMID 26355805
    .
  200. PMID 30410646
    .

Cited literature

Retrieved from "https://en.wikipedia.org/w/index.php?title=Deep_vein_thrombosis&oldid=1198375084"